Intrathecal clonidine added to small-dose bupivacaine prolongs postoperative analgesia in patients undergoing transurethral surgery

Agreta Gecaj-Gashi, MD;* Hasime Terziqi, MD;† Tune Pervorfi, MD;‡ Arben Kryeziu, MD*

*Clinic of Anesthesiology and ICU, University Clinical Center of Kosovo, Pristina, Republic of Kosovo; †Department of Plastic Surgery, University Clinical Center of Kosovo, Pristina, Republic of Kosovo; ‡Clinic of Urology, University Clinical Center of Kosovo, Pristina, Republic of Kosovo

Abstract

Introduction: The aim of this prospective, double-blinded study was to investigate the effects of clonidine in co-administration with bupivacaine during spinal anesthesia, regarding the onset and regression of motor and sensory block, postoperative analgesia and possible side effects.

Methods: We randomly selected 66 male patients (age 35 to 70), from the American Society of Anesthesiologists (ASA) class I-II; these patients were scheduled for transurethral surgical procedures. These patients were randomly allocated into two groups of 33 patients each: group B (bupivacaine) only received 0.5% isobaric bupivacaine 7.5 mg intrathecally and group BC (bupivacaine + clonidine) received bupivacaine 7.5 mg and clonidine 25 µg intrathecally. We performed the spinal anesthesia at a level of L3-L4 with a 25-gauge needle. We assessed the sensory block with a pin-prick, the motor block using the Bromage scale, analgesia with the visual analog scale and sedation with the modified Wilson scale. We also recorded the hemodynamic and respiratory parameters.

Results: The groups were demographically similar. The mean time of achievement of motor block (Bromage 3) and sensory block at level T9 was significantly shorter in the BC group compared with B group \( (p = 0.002, \ p = 0.000) \), respectively. The motor block regression time was not significantly different between the two groups \( (p = 0.237) \). The postoperative analgesia requirement was significantly longer in group BC compared with group B \( (p = 0.000) \). No neurological deficit, sedation or other significant adverse effects were recorded.

Conclusion: The intrathecal application of clonidine in combination with bupivacaine improves the duration and quality of spinal anesthesia; it also provides longer duration of postoperative analgesia, without significant side effects.

Introduction

Spinal anesthesia has been widely used for urologic operations, particularly in transurethral surgical procedures, because it permits early recognition of symptoms caused by overhydration, transurethral resection of prostate syndrome and bladder perforation.

Smaller doses of intrathecal bupivacaine will reduce the number of blocked dermatomes and decrease the duration of spinal anesthesia; the co-administration of clonidine reduces the dose of bupivacaine and improves the quality of spinal anesthesia.

The antinociceptive properties of clonidine indicate that it might be useful as an alternative to intrathecal opioids for postoperative analgesia, thus avoiding the main adverse effects, such as respiratory depression, pruritus and urinary retention. The intrathecal application of clonidine increases the duration of both sensory and motor block, as well as postoperative analgesia. The mechanism of clonidine in spinal anesthesia is reported to be mediated by presynaptic (inhibition of transmitter release) and postsynaptic (enhancing hyperpolarization) effects.

Marked decrease in arterial blood pressure was observed with 75 µg of intrathecal clonidine (in combination with intrathecal morphine), whereas relative hemodynamic stability was maintained with doses ≥150 µg, as demonstrated by using clonidine as the sole analgesic.

The aim of this prospective, randomized, double-blinded study was to evaluate the effects of clonidine in co-administration with bupivacaine during spinal anesthesia, regarding the onset and regression of motor block, sensory block, postoperative analgesia and possible side effects.

Methods

The hospital ethics committee of the University Clinical Centre of Kosovo approved the study and we obtained written informed consent from all patients. We randomly selected 66 male patients (age 35 to 70), American Society of Anesthesiologists (ASA) I-II who were scheduled for transurethral surgical procedures. We randomly allocated them into two groups (B [bupivacaine] and BC [bupivacaine + clonidine], with 33 patients in each group. Patients in group B...
received intrathecally 0.5% isobaric bupivacaine 7.5 mg and patients in group BC received 0.5% isobaric bupivacaine 7.5 mg plus 0.0015% clonidine 25 µg. These solutions were diluted with 0.9% saline solution to a total volume of 3.5 mL and were prepared by someone not involved in the patients' care. The anesthesiologist and the patients were blinded to the study solutions.

Patients taking α-adrenergic receptor antagonists, angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers were excluded from the study. We also excluded patients with psychiatric illness, neurologic disease, a body weight of >120 kg, a height of <150 cm, as well as patients belonging to the class ASA III-V and E.

Patients were not premedicated due to the evaluation of the potential sedation caused by clonidine. Before intrathecal injection, patients underwent standard monitoring (Datex-Ohmeda S/5 (TM) Monitor, Helsinki, Finland), including an electrocardiogram (5 lead), noninvasive blood pressure and pulse oximeter; we also noted baseline vital parameters. We obtained intravenous (IV) access with an 18-gauge IV needle, and cardiac arrest. All data collection was performed by people not involved in patient care. Patients were observed until the level of sensory block was S1 and the motor block was completely resolved (TRMB) (Bromage score: 0); patients were then discharged from the recovery room.

**Statistical analysis**

The results were analyzed using statistical software (Minitab 14, State College PA). Descriptive statistics are for all continuous variables denoted as mean (minimum-maximum) and ± standard deviation (SD). The comparisons for testing significant differences between the two groups BC and B (for continuous variables) were performed by using Student's t-test. While, Chi-square test ($\chi^2$) was used for categorical variables, such as ASA-Physical Status (PS) (I/II ratio). Statistical significance was set at $p < 0.05$.

**Results**

A total 66 patients were studied. There were no significant differences between the two groups with respect to age, height, weight and ASA status (Table 1).

We compared values (mean ± SD) of observed parameters regarding the onset of motor block, onset of sensory block, regression of motor block and regression of sensory block (Table 2).
A complete motor blockade of the lower extremities (Bromage 3) and sensory block of T9 were observed in all patients. The difference in time of achievement of complete motor block between groups was statistically significant (8.273 ± 1.941 min. in group BC vs. 9.697 ± 1.551 min. in group B), in favour of clonidine group (p = 0.002).

We also observed that the mean time to achieve sensory block of T10 was significantly shorter in the clonidine group (11.394 ± 2.150 min.) than in the plain bupivacaine group (15.758 ± 0.562 min.) (p = 0.000).

There were no statistically significant differences between the groups in the complete regression of motor block (Bromage scale 0); 236.48 ± 35.32 minutes versus 226.06 ± 35.65 minutes in the BC and B groups, respectively (p = 0.237). The regression of sensory block to S1, the first request for supplemental analgesia (VAS scores at >2 to 3 cm) was significantly longer in the BC group than in the B group (434.1 ± 78.3 min. vs. 263.97 ± 40.38 min., respectively, p=0.000).

The box plots provide useful information for comparing BC and B group in terms of TAMB, TASB, TRSB and TRMB. There is considerable spread in the median of TAMB and TASB, with group B having the higher median and group BC the lower median (Fig. 1). Additionally, we can observe that there is an outlier for TASB in group B. Unlike Fig. 1, Fig. 2 illustrates a higher median of TRSB in group BC compared to group B. The resulting box plots for TRMB in Fig. 2 do not illustrate significant differences in the median of group BC and B.

There was low incidence of side effects and no patient suffer from complications, such as transitory neurologic syndrome, headache, low back pain and cardiac arrest. The incidence of hypotension was 3 (9%) patients in the clonidine groups compared with 2 (6%) in the plain bupivacaine group. There were no events of bradycardia and respiratory depression in any of the treatment groups. Adverse effects, such as sedation, nausea, vomiting, pruritus, sweating and shivering, were not observed.

Discussion

Our results showed that the low dose of intrathecal clonidine co-administered with a low dose of bupivacaine increased the onset of motor block, onset and duration of sensory

**Table 1. Demographic and baseline characteristics of patients**

<table>
<thead>
<tr>
<th></th>
<th>BC group (N=33)</th>
<th>B group (N=33)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>59.64 (42-70)</td>
<td>59.24 (42-70)</td>
<td>0.856</td>
</tr>
<tr>
<td>±8.98</td>
<td>±8.86</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>90.18 (77-106)</td>
<td>86.24 (60-103)</td>
<td>0.097</td>
</tr>
<tr>
<td>±8.09</td>
<td>±10.74</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height (cm)</td>
<td>172.85 (163-180)</td>
<td>173.97 (158-182)</td>
<td>0.365</td>
</tr>
<tr>
<td>±4.74</td>
<td>±5.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASA-PS (I/II ratio)</td>
<td>21/12</td>
<td>22/11</td>
<td>0.796</td>
</tr>
</tbody>
</table>

BC: intrathecal bupivacaine + clonidine; B: intrathecal bupivacaine alone; ASA-PSL: American Society of Anesthesiologists Physical Status. Values shown as number (N) of patients, mean (min-max) ± standard deviation.

---

**Fig. 1.** Box plots of data between BC (intrathecal bupivacaine + clonidine) and B (intrathecal bupivacaine alone) group in terms of TAMB (time to achieve motor block Bromage 3 [minutes]) and TASB (time to achieve sensory block T10 [minutes]).
block (from time of first request for supplemental analgesia), without delaying motor block in patients undergoing transurethral surgical procedures.

Clonidine is a selective partial agonist for \( \alpha \)-2 adrenergic receptors; the analgesic effect following its intrathecal administration is mediated spinally through the activation of postsynaptic \( \alpha \)-2 receptors in substantia gelatinosa of the spinal cord.\(^{12,13}\)

Many previous studies have used intrathecal clonidine combined with opioids and local anesthetics for labour analgesia and orthopedic surgery,\(^{14-16}\) but not for urologic surgery, particularly transurethral surgical procedures. Gautier and colleagues recommend 15 to 45 \( \mu \)g of clonidine as optimal for supplementing spinal anesthesia;\(^{17}\) in keeping within this range, we chose 25 \( \mu \)g as optimal.

Clonidine (15-30 \( \mu \)g) significantly prolongs sensory blockade and improves postoperative analgesia for gynecological operations,\(^{18}\) knee arthroscopy,\(^{17}\) and ambulatory inguinal herniorrhaphy.\(^{19}\) The data match with our results concerning the duration of sensory block-postoperative analgesia. Our results showed that the addition of a small dose (25 \( \mu \)g) of clonidine increased the spread (onset-T9) and duration of sensory block, thereby prolonging postoperative analgesia.

According to some previous studies, intrathecal clonidine alone, even at doses above 450 \( \mu \)g, does not cause muscular weakness and motor blockade,\(^{11}\) but combined with local anesthetics it significantly enhances the intensity and duration of motor blockade.\(^{2,4}\) In our study, however, we found a significant difference in the TAMB between the two groups, in favour of the clonidine group, but we failed to achieve statistical significance in the duration of the motor block.

The higher doses of clonidine have been reported to cause important decreases in arterial pressure and marked sedation.\(^{11,20,21}\) However, as our results demonstrate, a small dose of intrathecal clonidine is not usually associated with systemic side effects, such as bradycardia, hypotension or sedation.\(^{17}\)

Relative hemodynamic stability was maintained in both groups. Patients receiving intrathecal clonidine showed small variations in hemodynamic variables which were not clini-
Intrathecal clonidine improves spinal analgesia for TRUS

cally relevant. In orthopaedic patients, some studies show that changes are not observed in hemodynamic variables with 150 µg. Relative cardiovascular stability has been reported with 75 to 100 µg, and a significantly decrease of blood pressure is reported with 75 µg intrathecal clonidine (in combination with 0.5 mg intrathecal morphine). Therefore, hemodynamic stability in our study can be attributed to a low dose of clonidine.

Sedation, a central effect of α-2 adrenergics, may occur after either systemic, epidural or intrathecal administration of clonidine, notably in the dose range of 150 to 450 µg. However, in our study sedation is not observed in any of the patients in BC group, which also could be explained by the use of a low dose of intrathecal clonidine.

We have not noted any significant adverse effects (e.g., respiratory depression, vomiting, nausea, pruritus, shivering, sweating) or complications (e.g., cardiac arrest, postdural puncture headache, backache, transitory neurologic syndrome) as recorded in previous studies.

**Conclusion**

This study showed that a small-dose of intrathecal clonidine (25 µg) as adjuvant to small-dose (7.5 mg) bupivacaine increased the onset and duration of analgesia and produced an effective spinal anesthesia in patients undergoing transurethral surgical procedures.

We suggest this adjuvant especially for ambulatory anesthesia because it prolongs postoperative analgesia, but not motor block.

**Competing interests:** None declared.

This paper has been peer-reviewed.

**References**


Correspondence: Dr. Agreta Gercz-Gercz, Kodra a dieitit RIII, Llrm. 34/4; 10000 Pristhine, Kosova; agrettag@yahoo.com